Abstract: The invention provides for LNA oligomers, for the treatment of a metabolic or liver disorder, wherein the LNA oligomer is administered orally in a unit dose of less than 50 mgs/kg, wherein the LNA oligomer is administered in the presence of a penetration (permeation) enhancer.
Type:
Grant
Filed:
October 20, 2010
Date of Patent:
June 14, 2016
Assignee:
Roche Innovation Center Copenhagen A/S
Inventors:
Gregroy Hardee, Ellen Marie Straarup, Marie Wickstrom Lindholm, Henrik Orum, Henrik Hansen
Abstract: The present invention provides, among other things, oligonucleotide modulators (e.g., inhibitors) of B cell lymphoma/leukemia 11A (BCL11A) and improved methods and composition for treating BCL11A-related diseases, disorders or conditions based on such modulators.
Abstract: The present invention is directed to novel double-stranded short interfering (siRNA) analogs comprising locked nucleic acid (LNA) monomers. Such compounds induces sequence-specific post-transcriptional gene silencing in many organisms by a process known as RNA interference (RNAi). The compounds disclosed herein has improved properties compared to non-modified siRNAs and may, accordingly, be useful as therapeutic agents, e.g., in the treatment of various cancer forms. More particularly, the present invention is directed to siRNA analogs comprising a sense strand and an antisense strand, wherein each strand comprises 12-35 nucleotides and wherein the siRNA analogs comprise at least one locked nucleic acid (LNA) monomer.
Type:
Grant
Filed:
February 11, 2014
Date of Patent:
March 29, 2016
Assignee:
Roche Innovation Center Copenhagen A/S
Inventors:
Joacim Elmen, Claes Wahlestedt, Zicai Liang, Anders M. Sorensen, Henrik Orum, Troels Koch
Abstract: The present invention relates to oligomer compounds (oligomers), which target APO-B100 mRNA in a cell, leading to reduced expression of APO-B100. Reduction of APO-B100 expression is beneficial for the treatment of certain medical disorders, such as diseases associated with apolipoproteinB activity, such as in non-limiting example, different types of HDL/LDL cholesterol imbalance; dyslipidemias, e.g., familial combined dyslipidemia (FCHL), acquired hyperlipidemia, hypercholesterolemia, statin-resistant hypercholesterolemia; coronary artery disease (CAD), coronary heart disease (CHD), atherosclerosis.
Type:
Grant
Filed:
June 14, 2010
Date of Patent:
March 22, 2016
Assignee:
Roche Innovation Center Copenhagen A/S
Inventors:
Niels Fisker Nielsen, Ellen Marie Straarup, Marie Wickstrom Lindholm
Abstract: The invention provides pharmaceutical compositions comprising short single stranded oligonucleotides, of length of between 8 and 26 nucleobases which are complementary to human microRNAs selected from the group consisting of miR19b, miR21, miR122a, miR155 and miR375. The short oligonucleotides are particularly effective at alleviating miRNA repression in vivo. It is found that the incorporation of high affinity nucleotide analogs into the oligonucleotides results in highly effective anti-microRNA molecules which appear to function via the formation of almost irreversible duplexes with the miRNA target, rather than RNA cleavage based mechanisms, such as mechanisms associated with RNaseH or RISC.
Type:
Grant
Filed:
April 4, 2014
Date of Patent:
September 15, 2015
Assignee:
Roche Innovation Center Copenhagen A/S
Inventors:
Joacim Elmén, Phil Kearney, Sakari Kauppinen
Abstract: The present invention provides compositions and methods of treatment of HCV infected subjects that are not sensitive to interferon treatment. Further, compositions and methods are provided for prevention of organ transplant rejection. The compositions of the invention comprise an anti microRNA-122 oligonucleotide, and are made for administration to a primate.
Type:
Grant
Filed:
April 26, 2010
Date of Patent:
May 19, 2015
Assignee:
Roche Innovation Center Copenhagen A/S
Inventors:
Elisabeth S. Hildebrandt-Eriksen, Andreas Petri, Sakari Kauppinen, Niels Abrahamsen, Robert Eldon Lanford